Loading...

Fusion Antibodies plc

FAB.LLSE
Healthcare
Biotechnology
£11.35
£0.35(3.18%)

Fusion Antibodies plc (FAB.L) Company Profile & Overview

Explore Fusion Antibodies plc’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Fusion Antibodies plc (FAB.L) Company Profile & Overview

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.

SectorHealthcare
IndustryBiotechnology
CEOAdrian Robert Kinkaid

Contact Information

44 28 9043 2800
1 Springbank Road, Belfast, BT17 0QL

Company Facts

27 Employees
IPO DateDec 18, 2017
CountryGB
Actively Trading

Frequently Asked Questions

;